Transdermal drug delivery system: Patent reviews

Recent Patents on Drug Delivery and Formulation

Volumn 3, Issue 2, 2009, Pages 143-152

  Samad, Abdus ^a   Ullah, Zabih ^a   Alam, Mohammad I ^a   Wais, Mohd ^a   Shams, Mohammad Shabaz ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Matrix; Patents; Reservoir; Review; Transdermal drug delivery system

Indexed keywords

DRUG; DRUG CARRIER; ESTRADIOL; ESTROGEN; GLYCERYL TRINITRATE; LIDOCAINE; NANOCARRIER; NICOTINE; PROTEIN; SCOPOLAMINE; VACCINE;

ANGINA PECTORIS; ANTIGEN PRESENTATION; CONTROLLED DRUG RELEASE; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG TRANSPORT; MENOPAUSAL SYNDROME; MOTION SICKNESS; PATENT; PATIENT COMPLIANCE; POSTHERPETIC NEURALGIA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SKIN PENETRATION; SKIN PERMEABILITY; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; CHEMISTRY; DELAYED RELEASE FORMULATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; PHARMACEUTICS; SKIN ABSORPTION;

ADMINISTRATION, CUTANEOUS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; SKIN ABSORPTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 68849116862     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221109788452294     Document Type: Review

References (123)

1. Rein H. Experimental electro endosmotic studies on living human skin. Z Biol 1924; 81: 124.
2. Gennaro AR. Remington's practice of pharmacy, 20th ed. In: Baltimore, MD. Ed. Lippincott Williams & Wilkins 2000; p. 836.
3. Bunge AL. Release rate from topical formulation containing drug in suspension. J Control Release 1998; 52: 141-148.
4. Wertz PW. Lipids and barrier function of the skin. Acta Derm Venereol Suppl (Stockh) 2000; 208: 7-11.
5. Kalia YN, Guy RH. Modelling transport drug release. Adv Drug Deliv Rev 2001; 48: 159-172.
6. Barry BW. Novel mechanism and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14: 101-114.
7. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004; 3: 115-124.
8. Ford JL, Rubeinstein MH, Hogan JE. Propranolol HCl and aminophyllin release from matrix tablet containing hydroxyl propyl methyl cellulose. Int J Pharm 1985; 24: 339-350.
9. Remunan LC, Portero A, Vila jato JL, Alonso MJ. Design and evaluation of chitosan, ethylcellulose mucoadhesive bilayered devices for buccal drug delivery. J Control Release 1998; 55: 143-152.
10. Cramer MP, Sacks SR. Value of controlled release dosage form. Pharmacoeconomics 1994; 5: 482-504.
11. Flyn GL, Bronaugh RL, Masbach RL, Eds In: Percutaneous absorbtion. Mercel Decker Inc New York 1985; 17-25.
12. Kasting GB, Smith RL, Anderson BD. In: Prodrugs, topical and ocular drug delivery. New York, Mercel Decker 1992; 53: 117-161.
13. Potts RO, Guy RH. Predicting skin permeability. Pharm Res 1992; 9: 663-672.
14. Higuchi WI. Analysis of data on the medicament release from ointments. J Pharm Sci 1962; 51: 802- 804.
15. Menon GK. New insights into skin structure: Scratching the surface. Adv Drug Deliv Rev 2002; 54: 3-17.
16. Fang SY. Transdermal drug delivery. In: Introduction to Biomaterials and Tissue Engineering. Academic Press, San Diego 2004; 3-40.
17. Chan TCK. Percutaneous permeation enhancers: An update. Excerpted from the Proceedings of the 9th Biennial International Conference of Perspectives in Percutaneous Permeation (2005), La Grand Motte, France, April 13, 2004.
18. Monika B, Bernhard CL. Percutaneous permeation enhancement and its quantification. Eur J Pharm Biopharm 1998; 46(1): 1-13.
19. Russell OP, Guia MG, Michael LF, Vivien HWM, Richard HG. Mechanism and enhancement of solute transport across the stratum corneum. J Control Release 1991; 15(3): 249-260.
20. Mutalik S, Udupa N. Pharmacological evaluation of membrane-moderated transdermal system of glipizide. Clin Exp Pharmacol Physiol 2006; 33 (1-2): 17-26.
21. Mutalik S, Udupa N. Formulation development, in vitro and in vivo evaluation of membrane controlled transdermal systems of glibenclamide. J Pharm Pharm Sci 2005; 8: 26-38.
22. Bagyalakshmi J, Vamsikrishna RP, Manavalan R, Ravi TK, Manna PK. Formulation development and in vitro and in vivo evaluation of membrane-moderated transdermal systems of ampicillin sodium in ethanol: pH 4.7 Buffer solvent system. AAPS Pharm Sci Tech 2007; 8 (1): 7.
23. Padula C, Nicoli S, Colombo P, Santi P. Single-layer transdermal film containing lidocaine: Modulation of drug release. Eur J Pharm Biopharm 2007; 66(3): 422-428.
24. Aqil M, Sultana Y, Ali A. Transdermal delivery of beta-blockers. Expert Opin Drug Deliv 2006; 3(3): 405-418.
25. Langer R. Transdermal drug delivery: Past progress, current status and future prospects. Adv Drug Deliv Rev 2004; 56: 557-558.
26. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev 2004; 3: 115-124.
27. Jain N, Talegonkar S, Jain NK. New ways to enter the blood stream: Emerging strategies in transdermal drug delivery. Pharm Rev 2004; 41-59.
28. Barry B. Transdermal drug delivery. In: Aulton EM, Ed. Pharmaceutics. The science of dosage forms design. Churchill Livingstone, New York, Harcourt Publishers 2002: 499-433.
29. Kumar R, Philip A. Modified transdermal technologies: Breaking the barriers of drug permeation via the skin. Trop J Pharm Res 2007; 6(1): 633-644.
30. Chien YW. Novel drug delivery systems. Drugs and the pharmaceutical Sciences. New York, Marcel Dekker 1992; p. 797.
31. Finnin CB. Transdermal drug delivery-What to expect in the near future. Bus briefing: Pharma Tech 2003; 16 (1): 192-193.
32. Chien YW. Transdermal drug delivery and delivery system; Marcel Drugs and the pharmaceutical sciences. New York, Marcel Dekker 1992; pp. 301-381.
33. Mutalik S, Udupa S, Kumar S, Agarwal S, Subramanian G, Ranjith AK. Glipizide matrix transdermal systems for diabetes mellitus: Preparation, in vitro and preclinical studies. Life Sci 2006; 79(16): 1568-1577.
34. Csóka G, Pásztor E, Marton S, Zelkó R, Antal I, Klebovich I. Formulation of thermoresponsive transdermal therapeutic systems using cellulose derivatives. Acta Pharm Hung 2007; 77(2): 102-107.
35. Aqil M, Sultana Y, Ali A. Matrix type transdermal drug delivery systems of metoprolol tartrate: in vitro Characterization. Acta Pharm 2003; 53(2): 119-125.
36. Kakubari I, Sasaki H, Takayasu T, Yamauchi H, Takayama S, Takayama K. Effects of ethylcellulose and 2-octyldodecanol additives on skin permeation and irritation with ethylene-vinyl acetate copolymer matrix patches containing formoterol fumarate. Biol Pharm Bull 2006; 8: 1717-1722.
37. Ubaidulla U, Reddy MVS, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. AAPS Pharm Sci Tech 2007; 8(1): 2-6.
38. Lipp, R., Laurent, H., Gunther, C., Riedl, J., Esperling, P., Tauber, U.: US5858394 (1999).
39. Heiber, W., Andriola, R., Williams, P., Ebert, C.: US4911707 (1990).
40. Patricia, S., Campbell, J., Eckenhoff, B.: US4704282 (1987).
41. Mueller, W.: US20030099695 (2003).
42. Math, M.C., Teillaud, E., Bevan, B.: US20006013276 (2000).
43. Becher, F.: US5066494 (1991).
44. Dittgen, M., Fricke, S., Volkel, C., Ahrens, K., Gerecke, H., Kopke, K.: US20030044453 (2003).
45. Becher, F.: RE34692 (1994).
46. Horstmann, M., Muller, W., Laux, W.: US20016277400 (2001).
47. Windt-hanke, F., Gunther, C., Horowski, R., Tack, J., Engfer, A., Bostedt, K, T., Schenk, D.: US20070243240 (2007).
48. Meconi, R., Seibertz, F., Horstmann, M., Lichtenberger, R..: US20006143319 (2000).
49. Davis, R., Primo-davis, S.A.: US5665378 (1997).
50. Schwarz, P.A.G.: US20026461636 (2002).
51. Enscore, D.J., Gale, R.M.: US4559222 (1985).
52. Schenk, D., Meyer, E., Woess, A., Mcleod, S.: US20040166148 (2004).
53. Wolff, H.M., Arth, C.: US20036555131 (2003).
54. Arth, C., Kollmeyer-Seeger, A., Rimpler, S., Wolff, H.M.: US20036555129 (2003).
55. Selzer, T.: US20010033859 (2001).
56. Beier, C., Wilhelm, M.: US20087344733 (2008).
57. Wolff, H.M.: US20060216336 (2006).
58. Selzer, T.: US20040101551 (2004).
59. Chiang, C., Tenzel, R. A.: US5980932 (1999).
60. Tanwar Y, Chauhan C, Sharma A. Development and evaluation of carvedilol transdermal patches. Acta Pharm 2007; 57: 151-159.
61. Gannu R, Kishan YV, Rao YM. Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. Curr Drug Deliv 2007; 4: 69-76.
62. Kawahara K, Tojo K. Skin irritation in transdermal drug delivery systems: A strategy for its reduction. Pharm Res 2007; 24(2): 399-408.
63. Aqil M, Chowdhary BI, Sultana Y, Talegaonkar S, Ahmad FJ, Ali MM. Transdermal therapeutic system of enalapril maleate using piperidine as permeation enhancer. Curr Drug Deliv 2008; 5(2): 148-152.
64. Gupta SP, Jain SK. Transdermal atenolol releasing system: An approach towards its development. J Drug Target 2006; 9: 607-613.
65. Aqil M, Sultana Y, Ali A, Dubey K, Najmi AK, Pillai KK. Transdermal drug delivery systems of a beta blocker: Design, in vitro and in vivo characterization. Drug Deliv 2004; 1: 27-31.
66. Azeem A, Jain N, Iqbal Z, Ahmad FJ, Aqil M, Talegaonkar S. Feasibility of proniosomes-based transdermal delivery of frusemide: Formulation optimization and pharmacotechnical evaluation. Pharm Dev Technol 2008; 13: 155-163.
67. Chien YW. New developments in drug delivery systems. Med Res Rev 2006; 10(4): 477-504.
68. Hille, T., Deurer, L.: US20046814976 (2004).
69. Horstmann, M., Muller, W., Laux, W.: US20016277400 (2001).
70. Anhauser, D., Deurer, L., Hille, T., Steinborn, P.: US20016315854 (2001).
71. Davis, R., Primo-davis, S.A.: US5665378 (1997).
72. Kugelmann, H., Bartholomaeus, J.: US20070298091 (2007).
73. Fankhauser, P., Schenkel, L.: US5128124 (1992).
74. Wolff, H. M.: US20060216336 (2006).
75. Bracht, S.: US20016238362 (2001).
76. Arth, C., Meese, C., Schacht, D.W., Wolff, H.M.: US20046783769 (2004).
77. Osborne, J.L., Nelson, M., Enscore, D.J., Yum, Su. Il., Gale, R.M.: US20006165497 (2000).
78. Mueller, W.: US20030099695 (2003).
79. Chandrasekaran, S.K., Darda, S., Michaels, A.S., Cleary, G.W.: US4201211 (1980).
80. Royds, R. B.: US20080008747 (2008).
81. Selzer, T.: US20030013726 (2003).
82. Todhunter, J.A.: US20080286348 (2008).
83. Altenschopfer, P., Watkinson, A.C.: US20060177493 (2006).
84. Nedberge, D. E., Gale, R. M., Crisologo, N. M., Wen, J., Imbert, D. C., Luciano, A., Silverberg, E.N., Foreman, P.B., Geerke, J.H.: US20070134310 (2007).
85. Audett, J., Goldman, E.J., Imbert, D.C., Nedberge, D.E., Wen, J., Luciano, A., Silverberg, E.N., Foreman, P.B., Geerke, J.H.: US20070104771 (2007).
86. Westcott, T.D., Stepic, J., Imbert, D.C., Audett, J., Wen, J., Luciano, A., Silverberg, E.N., Foreman, P.B.: US20070098772 (2007).
87. Samour, C.: US4910020 (1990).
88. Heiber, W., Andriola, R., Williams, P., Ebert, C.: US4917676 (1990).
89. Venkatraman, S.S., Stein, T.M., Snider, J., Hamlin, R.D.: US20050048104 (2005).
90. Horowski, R., Tack, J., Engfer, A.: US20040028723 (2004).
91. Wolff, H.M., Arth, C.: US20036562367 (2003).
92. Yum, Su. II., Theeuwes, F.: US20080206314 (2008).
93. Shevchuk, I., Cassidy, J.P., Reidenberg, B., Sharp, D.E., Kupper, R.J.: EP1476141B1 (2008).
94. Dean CH, Alarcon JB, Waterston AM, et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum Vaccin 2005; 1(3): 106-111.
95. Mikszta JA, Dekker JP 3rd, Harvey NG, et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 2006; 74(12): 6806-6810.
96. Chabri F, Bouris K, Jones T, et al. Microfabricated silicon microneedles for nonviral cutaneous gene delivery. Br J Dermatol 2004; 150(5): 869-877.
97. Gerstel, M. S., Place, V. A.: US3964482 (1976).
98. Trautman, J., Wong, P. S., Daddona, P. E., Kim, H. L., Zuck, M. G.: US20016322808 (2001).
99. McAllister DV, Wang PM, Davis SP, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. Proc Natl Acad Sci USA 2003; 100: 13755-13760.
100. Jacobsen, L.O., Kreilgard, B., Hoeck, U., Kristensen, H.: US20036517864 (2003).
101. Hoeck, U., Kreilgaard, B., Kristensen, H.: US20026335030 (2002).
102. Sherman, F. F., Gartstein, V.: US20046821281 (2004).
103. Xu B.: US20080051695 (2008).
104. Price, R. R., Schnur, J. M., Schoen, P. E., Testoff, M., Jacque Jr., G. H., Rudolph, A., Brady, R. F.: US20010026802 (2001).
105. Xu, B.: US20080214987 (2008).
106. Haley, J.T.: US20090010997 (2009).
107. Hamada, A., Kasahara, T., Ishikura, J., Funahashi, M., Ebe, H., Imoto, E., Habu, T.: US20090010995 (2009).
108. Uchida, N., Kuribayashi, M.: US20090004255 (2009).
109. Saeki, M., Wakamatsu, M., Yoshinaga, T.: EP1925299A1 (2008).
110. Miller, K.J., Govil, S.K., Bhatia, K.S.: US20070259027 (2007).
111. Cilurzo, F., Tosi, L.: EP1496874B1 (2007).
112. Stefano, F., Evaristo, J., Alejandro, F.: EP1503743B1 (2007).
113. Govil, S., K., Weimann, J.: US20067150881 (2006).
114. Yasukochi, T., Yamaguchi, T., Tateishi, T., Higo, N.: US20067034083 (2006).
115. Kanios, D., Hartwig, R.: US20060078601 (2006).
116. Yasukochi, T., Tateishi, T., Higo, N.: US20050266063 (2005).
117. Stefano, F.J.E., Scasso, A. F.: US20050208116 (2005).
118. Kanios, D.P., Hartwig, R., Mantelle, J.A., Houze, D.W.: US20050169977 (2005).
119. Ikesue, A., Tateishi, N., Uemura, K., Terahara, T., Higo, N., Sakai, M.: US20050163831 (2005).
120. Terahara, T., Aida, K., Toshimitsu, A., Higo, N.: EP1541177A1 (2005).
121. Houze, D.: US20050019385 (2005).
122. Govil, S.K.: US20040137046 (2004).
123. Miller, K.J., Govil, S.K., Bhatia, K.S.: US20040086551 (2004).